Clinical Trial Detail

NCT ID NCT04291105
Title Phase 2 Trial of Voyager V1 in Combination With Cemiplimab in Cancer Patients
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors Vyriad, Inc.
Indications

hepatocellular carcinoma

endometrial adenocarcinoma

lung non-small cell carcinoma

melanoma

Therapies

Cemiplimab + VSV-hIFNbeta-NIS

Age Groups: adult senior

No variant requirements are available.